-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies
M Allen Moseley, Mark T Dransfield
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies
M Allen Moseley, Mark T Dransfield
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies
M Allen Moseley, Mark T Dransfield
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies
M Allen Moseley, Mark T Dransfield
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies
M Allen Moseley, Mark T Dransfield
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies
M Allen Moseley, Mark T Dransfield
Review: Clinical Trail Outcomes: Clinical Investigation
-
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Omer Khalid ,Bruce R Bacon
Review Article: Clinical Investigation
-
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Omer Khalid ,Bruce R Bacon
Review Article: Clinical Investigation
-
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Omer Khalid ,Bruce R Bacon
Review Article: Clinical Investigation
-
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Omer Khalid ,Bruce R Bacon
Review Article: Clinical Investigation
-
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Omer Khalid ,Bruce R Bacon
Review Article: Clinical Investigation
-
Boceprevir in the treatment of hepatitis C infection: rationale and clinical data
Omer Khalid ,Bruce R Bacon
Review Article: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation